Mechanism of Action
pH-Dependent GCC Activation
Plecanatide is a structural analog of uroguanylin, which is the natural GCC agonist secreted by duodenal enteroendocrine cells. The peptide binds GCC on intestinal epithelial cells, increasing intracellular cGMP and activating CFTR chloride channels. The pH-dependent binding profile mirrors uroguanylin, concentrating activity in the small intestine where the natural hormone normally acts.
Fluid Secretion and Transit
Elevated luminal cGMP increases fluid and electrolyte secretion into the intestinal lumen via CFTR and inhibition of NHE3 sodium-hydrogen exchangers. This increases luminal water content, softens stool, and accelerates colonic transit. Paracrine effects on submucosal neurons also modulate visceral sensation.
Research Summary
CIC Pivotal Trials
FDA ApprovedTwo phase 3 trials demonstrated that plecanatide 3 mg significantly increased complete spontaneous bowel movement frequency versus placebo over 12 weeks. Approximately 21-22% of patients achieved the primary responder endpoint versus 10-14% on placebo. Stool consistency and straining scores also improved significantly.
IBS-C Efficacy
FDA ApprovedPhase 3 IBS-C trials showed significant improvements in abdominal pain and bowel movement frequency with plecanatide 3 mg. The responder rate was approximately 30% versus 18% on placebo. Safety and tolerability profiles were consistent with the CIC trials.
Calculate your Plecanatide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| CIC treatment | 3 mg | Once daily | Oral, with or without food |
| IBS-C treatment | 3 mg | Once daily | Oral, with or without food |
Contraindicated in pediatric patients under 6 years. Same pediatric contraindication as linaclotide.
Interactions
Safety Profile
Diarrhea is the most common adverse effect (5% of patients). Severe diarrhea requiring discontinuation is less frequent than with linaclotide. Systemic absorption is negligible (<1%), limiting systemic adverse effects. Contraindicated in children under 6 years. No significant drug interactions due to minimal systemic bioavailability.
References
- [1]Miner PB Jr et al. (2017). Plecanatide in the treatment of chronic idiopathic constipation: a randomized placebo-controlled trial. Therapeutic Advances in Gastroenterology, 10(2), 153-163.
- [2]Brenner DM et al. (2018). Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation. American Journal of Gastroenterology, 113(5), 735-745.